Oslo, 28 January 2021: Ultimovacs ASA ("Ultimovacs", ticker ULTI), today
announced that the lead investigator of the Company's NIPU Phase II clinical
trial, Åslaug Helland from Oslo University Hospital, has presented a poster with
an overview of the NIPU trial at the 2020 World Conference on Lung Cancer in
Singapore.  For more information on the NIPU trial and the poster that was
presented today, please refer to Ultimovacs corporate website.  

About UV1
UV1 is a peptide-based vaccine inducing a specific T cell response against the
universal cancer antigen telomerase. UV1 is being developed as an
"off-the-shelf" therapeutic cancer vaccine which may serve as a platform for use
in combination with other immunotherapy which requires an ongoing T cell
response for their mode of action. UV1 has been tested in four phase I clinical
trials which enrolled a total of 82 patients and has maintained a positive
safety and tolerability profile as well as encouraging signals of efficacy. 

About Ultimovacs
Ultimovacs' UV1 universal cancer vaccine candidate leverages the high prevalence
of the human telomerase (hTERT) to be effective across the dynamic stages of the
tumor's growth and its microenvironment. By directing the immune system to hTERT
antigens that are present in over 80% of all cancers, UV1 drives CD4 helper T
cells to the tumor with the goal of activating an immune system cascade to
increase anti-tumor responses. Ultimovacs' strategy is to clinically demonstrate
UV1's impact in a range of cancers and in several immunotherapy combinations
while expanding our pipeline of cancer vaccine therapies, convinced that a
universal approach may be the key to achieving better outcomes for patients.



For further information, please see www.ultimovacs.com or contact:

Carlos de Sousa, CEO 
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507 
	
Hans Vassgård Eid, CFO 
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632